Basic Information
Develop specific immunomodulatory biologics for organ transplantation, stem cell transplantation, and gene therapy. The candidate drug, Siplizumab, is a monoclonal antibody in the late stage of clinical development, which has shown great potential to change the lives of organ transplant patients by allowing complete cessation of all immunosuppressive treatments and return to normal life.